{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T01:00:13Z","timestamp":1760403613329,"version":"build-2065373602"},"reference-count":134,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.euroneuro.2010.05.003","type":"journal-article","created":{"date-parts":[[2010,6,4]],"date-time":"2010-06-04T04:32:39Z","timestamp":1275625959000},"page":"731-746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The \u03b12 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats"],"prefix":"10.1016","volume":"20","author":[{"given":"Svetlana","family":"Semenova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athina","family":"Markou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"1994","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","key":"10.1016\/j.euroneuro.2010.05.003_bib1"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF00172774","article-title":"Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system","volume":"352","author":"Andersson","year":"1995","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib3","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0024-3205(97)00801-1","article-title":"Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats","volume":"61","author":"Aricioglu-Kartal","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib4","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199103143241107","article-title":"Clozapine: a novel antipsychotic agent","volume":"324","author":"Baldessarini","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.npp.1300343","article-title":"The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice","volume":"29","author":"Barr","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/sj.npp.1301192","article-title":"Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats","volume":"32","author":"Bruijnzeel","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0893-133X(95)00068-O","article-title":"New insights into the biology of schizophrenia through the mechanism of action of clozapine","volume":"13","author":"Brunello","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib8","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2165\/00003495-200868080-00005","article-title":"Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status","volume":"68","author":"Buchhalter","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0376-8716(99)00064-2","article-title":"Dissociation of physical abstinence signs from changes in extracellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats","volume":"58","author":"Carboni","year":"2000","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 4","key":"10.1016\/j.euroneuro.2010.05.003_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/PL00014183","article-title":"Neurotransmitter interactions in schizophrenia: therapeutic implications","volume":"249","author":"Carlsson","year":"1999","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01276460","article-title":"The selective 5-HT2A receptor antagonist MDL 100, 907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse: implications for psychosis","volume":"100","author":"Carlsson","year":"1995","journal-title":"J Neural Transm Gen Sect"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF00168948","article-title":"Effect of alpha 2-adrenoceptor agonists on the expression of morphine-withdrawal in rats","volume":"345","author":"Coupar","year":"1992","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00213-003-1445-7","article-title":"Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat","volume":"168","author":"Cryan","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1124\/mol.104.001313","article-title":"Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors","volume":"66","author":"Damaj","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib17","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0022-3565(25)12943-1","article-title":"Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan","volume":"277","author":"de Boer","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib18","first-page":"123","article-title":"M-100907 (Aventis)","volume":"2","author":"de Paulis","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0306-4522(94)90179-1","article-title":"Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system","volume":"59","author":"De Vos","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0006-8993(91)91675-Q","article-title":"Autoradiographic distribution of alpha 2 adrenoceptors, NAIBS, and 5-HT1A receptors in human brain using [3H]idazoxan and [3H]rauwolscine","volume":"566","author":"De Vos","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1476-5381.1983.tb08809.x","article-title":"Studies on RX 781094: a selective, potent and specific antagonist of \u03b12-adrenoceptors","volume":"78","author":"Doxey","year":"1983","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1527-3458.2006.00178.x","article-title":"Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent","volume":"12","author":"Dwoskin","year":"2006","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s002130050321","article-title":"The influence of chronic treatment with clonidine, yohimbine and idazoxan on morphine withdrawal","volume":"132","author":"El-Kadi","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/30001","article-title":"Dramatic decreases in brain reward function during nicotine withdrawal","volume":"393","author":"Epping-Jordan","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0014-2999(02)01543-1","article-title":"In vivo tonic modulation of the noradrenaline release in the rat cortex by locus coeruleus somatodendritic alpha(2)-adrenoceptors","volume":"442","author":"Fernandez-Pastor","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib26","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0028-3908(83)90198-3","article-title":"Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic beta-adrenergic, serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain","volume":"22","author":"Ferris","year":"1983","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib27","first-page":"74","article-title":"Studies of bupropion's mechanism of antidepressant activity","volume":"44","author":"Ferris","year":"1983","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 12","key":"10.1016\/j.euroneuro.2010.05.003_bib28","first-page":"16","article-title":"Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies","volume":"62","author":"Frazer","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0091-3057(95)02063-2","article-title":"Effects of nicotine withdrawal on central dopaminergic systems","volume":"53","author":"Fung","year":"1996","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archpsyc.1996.01830090049008","article-title":"Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims","volume":"53","author":"Garcia-Sevilla","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0014-2999(91)90204-4","article-title":"Effects of idazoxan on dorsal raphe 5-hydroxytryptamine neuronal function","volume":"193","author":"Garratt","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib32","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1001\/jama.1988.03720190031026","article-title":"Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial","volume":"259","author":"Glassman","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0893-133X(99)00035-4","volume":"21","author":"Gobert","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00008877-199812000-00006","article-title":"Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: tests with subtype selective receptor ligands","volume":"9","author":"Goudie","year":"1998","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.1994.11","article-title":"A placebo-controlled study of three clonidine doses for smoking cessation","volume":"55","author":"Gourlay","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib36","first-page":"CD000058","article-title":"Clonidine for smoking cessation","volume":"3","author":"Gourlay","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1304.001","article-title":"Relevance of imidazoline receptors and agmatine to psychiatry: a decade of progress","volume":"1009","author":"Halaris","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0893-133X(00)00237-2","article-title":"Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats","volume":"25","author":"Harrison","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0022-3565(24)29542-2","article-title":"Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors","volume":"297","author":"Harrison","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1126\/science.286.5437.105","article-title":"Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by \u03b12 adrenoceptor blockade","volume":"286","author":"Hertel","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0014-2999(99)00175-2","article-title":"Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level","volume":"371","author":"Hertel","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib42","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0006-8993(97)01135-9","article-title":"Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome","volume":"779","author":"Hildebrand","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib43","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0893-133X(99)00055-X","article-title":"Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: role of nicotinic receptors in the ventral tegmental area","volume":"21","author":"Hildebrand","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib44","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s007020070038","article-title":"Intraaccumbal mecamylamine infusion does not affect dopamine output in the nucleus accumbens of chronically nicotine-treated rats","volume":"107","author":"Hildebrand","year":"2000","journal-title":"J Neural Transm"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib45","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib46","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2014the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib47","first-page":"CD000031","article-title":"Antidepressants for smoking cessation","volume":"4","author":"Hughes","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib48","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199710233371703","article-title":"A comparison of sustained-release bupropion and placebo for smoking cessation","volume":"337","author":"Hurt","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib49","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","article-title":"5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release","volume":"76","author":"Ichikawa","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(98)00308-2","article-title":"Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens","volume":"351","author":"Ichikawa","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-8993(02)03570-9","article-title":"Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism","volume":"956","author":"Ichikawa","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib52","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0028-3908(02)00166-1","article-title":"Differential regulation of nicotinic receptor-mediated neurotransmitter release following chronic (\u2212)-nicotine administration","volume":"43","author":"Jacobs","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib53","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuropharm.2008.05.025","article-title":"Serotonergic approaches in the development of novel antipsychotics","volume":"55","author":"Jones","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib54","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199903043400903","article-title":"A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation","volume":"340","author":"Jorenby","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib55","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1124\/jpet.103.052027","article-title":"Group II metabotropic and \u03b1-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)\/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats","volume":"306","author":"Kenny","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib56","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0091-3057(01)00651-7","article-title":"Neurobiology of the nicotine withdrawal syndrome","volume":"70","author":"Kenny","year":"2001","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archpsyc.1979.01780030055004","article-title":"Intracranial self-stimulation thresholds: a model for the hedonic effects of drugs of abuse","volume":"36","author":"Kornetsky","year":"1979","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib58","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.1999.tb09350.x","article-title":"Inhibition of central monoamine oxidase by imidazoline2 site-selective ligands","volume":"881","author":"Lalies","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF00421544","article-title":"Amphetamine and the reward system: evidence for tolerance and post-drug depression","volume":"46","author":"Leith","year":"1976","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib60","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nrd2361","article-title":"Translational research in medication development for nicotine dependence","volume":"6","author":"Lerman","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0376-8716(02)00067-4","article-title":"Mediating mechanisms for the impact of bupropion in smoking cessation treatment","volume":"67","author":"Lerman","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib62","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1017\/S0033291709005455","article-title":"Second-generation antipsychotics for schizophrenia: can we resolve the conflict?","volume":"39","author":"Leucht","year":"2009","journal-title":"Psychol Med"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib63","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00213-005-0170-9","article-title":"ACP-103, a 5-HT2A\/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens","volume":"183","author":"Li","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib64","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-8993(02)02620-3","article-title":"5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner","volume":"947","author":"Liegeois","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib65","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s002130051060","article-title":"Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat: interactions between the two drugs","volume":"145","author":"Lin","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib66","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0091-3057(99)00213-0","article-title":"Time-dependent alterations in ICSS thresholds associated with repeated amphetamine administrations","volume":"65","author":"Lin","year":"2000","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib67","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1192\/bjp.168.5.571","article-title":"Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine","volume":"168","author":"Litman","year":"1996","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib68","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1017\/S1461145708009267","article-title":"Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action","volume":"12","author":"Lopez-Gil","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib69","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0149-7634(95)00061-5","article-title":"Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence","volume":"21","author":"Maldonado","year":"1997","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib70","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0091-3057(92)90408-8","article-title":"Rodent model of nicotine abstinence syndrome","volume":"43","author":"Malin","year":"1992","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib71","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1017\/S1461145705005328","article-title":"Combined \u03b12 and D2\/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat","volume":"8","author":"Marcus","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib72","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00213-004-2008-2","article-title":"Paroxetine combined with a 5-HT1A receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats","volume":"178","author":"Markou","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib73","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF02245878","article-title":"Desmethylimipramine attenuates cocaine withdrawal in rats","volume":"109","author":"Markou","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib74","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/10298420290023963","article-title":"Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories","volume":"4","author":"Markou","year":"2002","journal-title":"Neurotox Res"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib75","first-page":"17","article-title":"Postcocaine anhedonia: an animal model of cocaine withdrawal","volume":"4","author":"Markou","year":"1991","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib76","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0031-9384(92)90211-J","article-title":"Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations","volume":"51","author":"Markou","year":"1992","journal-title":"Physiol Behav"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib77","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0014-2999(97)01544-6","article-title":"Effects of idazoxan on dopamine release in the prefrontal cortex of freely moving rats","volume":"343","author":"Matsumoto","year":"1998","journal-title":"Eur J Pharmacol"},{"issue":"Suppl B","key":"10.1016\/j.euroneuro.2010.05.003_bib78","first-page":"47","article-title":"An overview of the mechanism of action of clozapine","volume":"55","author":"Meltzer","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib79","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","article-title":"In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems","volume":"172","author":"Meltzer","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib80","first-page":"390","article-title":"The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs","volume":"25","author":"Meltzer","year":"1989","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib81","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00008877-199909000-00006","article-title":"Rapid recovery of self-stimulation responding from depression by clozapine is prevented by the alpha 2-adrenoceptor agonist, clonidine","volume":"10","author":"Montgomery","year":"1999","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib82","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.fbp.0000080415.40539.b9","article-title":"Alpha2-adrenoceptor antagonism is neither sufficient nor necessary for the distinctive action of atypical neuroleptics on intracranial self-stimulation in the rat","volume":"14","author":"Montgomery","year":"2003","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib83","first-page":"87","article-title":"Clonidine for smoking cessation","volume":"81","author":"Nana","year":"1998","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib84","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00001756-199903170-00007","article-title":"Nicotine withdrawal in the rat: role of \u03b17 nicotinic receptors in the ventral tegmental area","volume":"10","author":"Nomikos","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib85","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF02244765","article-title":"Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex","volume":"115","author":"Nomikos","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib86","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1995.tb32397.x","article-title":"Functional studies of specific imidazoline-2 receptor ligands","volume":"763","author":"Nutt","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib87","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/026988119701100209","article-title":"Noradrenergic mechanisms in the prefrontal cortex","volume":"11","author":"Nutt","year":"1997","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib88","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/archpsyc.1989.01810100100021","article-title":"Idazoxan: a selective \u03b12-antagonist and effective sustained antidepressant in two bipolar depressed patients","volume":"46","author":"Osman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"1 Suppl","key":"10.1016\/j.euroneuro.2010.05.003_bib89","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1007\/BF02245008","article-title":"Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function","volume":"112","author":"Palfreyman","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib90","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1749-6632.1995.tb32394.x","article-title":"Imidazoline binding sites. Pharmacological and molecular characteristics","volume":"763","author":"Parini","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib91","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0022-3565(25)10596-X","article-title":"Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine","volume":"274","author":"Parsons","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib92","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0166-4328(96)00101-5","article-title":"Extracellular serotonin is decreased in the nucleus accumbens during withdrawal from cocaine self-administration","volume":"73","author":"Parsons","year":"1996","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib93","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/syn.890090109","article-title":"Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine","volume":"9","author":"Parsons","year":"1991","journal-title":"Synapse"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib94","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0165-0270(91)90063-6","article-title":"The in vivo microdialysis recovery of dopamine is altered independently of basal level by 6-hydroxydopamine lesions to the nucleus accumbens","volume":"40","author":"Parsons","year":"1991","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib95","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/14622200802097571","article-title":"Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats","volume":"10","author":"Paterson","year":"2008","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03033479","article-title":"Animal models and treatments for addiction and depression co-morbidity","volume":"11","author":"Paterson","year":"2007","journal-title":"Neurotox Res"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib97","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s002130000559","article-title":"Effects of repeated withdrawal from continuous amphetamine administration on brain reward function in rats","volume":"152","author":"Paterson","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib98","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00213-008-1144-5","article-title":"The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat","volume":"198","author":"Paterson","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0006-8993(00)03004-3","article-title":"M100, 907, a selective 5-HT2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex","volume":"888","author":"Pehek","year":"2001","journal-title":"Brain Res"},{"year":"1986","series-title":"A Stereotaxic Atlas of the Rat Brain","author":"Pellegrino","key":"10.1016\/j.euroneuro.2010.05.003_bib100"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib101","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0149-7634(89)80017-X","article-title":"Neurochemical correlates of brain-stimulation reward measured by ex vivo and in vivo analyses","volume":"13","author":"Phillips","year":"1989","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib102","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1037\/0021-843X.112.1.3","article-title":"Smoking withdrawal dynamics: I. Abstinence distress in lapsers and abstainers","volume":"112","author":"Piasecki","year":"2003","journal-title":"J Abnorm Psychol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib103","first-page":"107","article-title":"Alpha 2-adrenoceptor antagonists as antidepressants: the search for selectivity","volume":"3","author":"Pinder","year":"1987","journal-title":"Psychopharmacol Ser"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib104","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1001\/archinte.1992.00400220083015","article-title":"Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation","volume":"152","author":"Prochazka","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib105","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/archinte.158.18.2035","article-title":"A randomized trial of nortriptyline for smoking cessation","volume":"158","author":"Prochazka","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib106","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s002130100781","article-title":"Effects of nicotine and mecamylamine-induced withdrawal on extracellular dopamine and acetylcholine in the rat nucleus accumbens","volume":"157","author":"Rada","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejphar.2004.04.044","article-title":"Effects of nicotine preexposure on sulpiride-induced dopamine release in the nucleus accumbens","volume":"494","author":"Rahman","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib108","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-3223(00)00850-7","article-title":"5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex","volume":"48","author":"Rollema","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib109","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0014-2999(94)00698-7","article-title":"The selective 5-HT2A receptor antagonist, MDL 100, 907, increases dopamine efflux in the prefrontal cortex of the rat","volume":"273","author":"Schmidt","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14728214.11.3.429","article-title":"Current and emerging pharmacotherapies for treating tobacco dependence","volume":"11","author":"Schnoll","year":"2006","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib111","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0006-3223(03)00240-3","article-title":"Clozapine treatment attenuated somatic and affective signs of nicotine and amphetamine withdrawal in subsets of rats exhibiting hyposensitivity to the initial effects of clozapine","volume":"54","author":"Semenova","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib112","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00008877-199608000-00004","article-title":"Modification of naloxone-precipitated withdrawal symptoms in mice by drugs acting on alpha(2)-adrenoceptors","volume":"7","author":"Sharif","year":"1996","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib113","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s002130050022","article-title":"The effect of bupropion on nicotine craving and withdrawal","volume":"148","author":"Shiffman","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib114","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00008877-199512000-00010","article-title":"DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT2A and not by 5-HT2C receptors","volume":"6","author":"Sipes","year":"1995","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00429-008-0191-3","article-title":"Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence","volume":"213","author":"Smith","year":"2008","journal-title":"Brain Structure Function"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib116","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0022-3565(25)38366-7","article-title":"Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies","volume":"266","author":"Sorensen","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib117","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s002130100866","article-title":"Cessation of chronic nicotine administration enhances wet-dog shake responses to 5-HT2 receptor stimulation in rats","volume":"159","author":"Suemaru","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib118","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.pnpbp.2003.09.009","article-title":"\u03b1-Adrenoceptor modulation hypothesis of antipsychotic atypicality","volume":"27","author":"Svensson","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib119","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0006-8993(01)03121-3","article-title":"Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons","volume":"922","author":"Szabo","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib120","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuropharm.2009.06.035","article-title":"Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine","volume":"57","author":"Taksande","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib121","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00165728","article-title":"\u03b12-Adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo","volume":"345","author":"Tao","year":"1992","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib122","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0166-4328(99)00127-8","article-title":"Effects of agmatine on ethanol withdrawal syndrome in rats","volume":"107","author":"Uzbay","year":"2000","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib123","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/sj.npp.1301173","article-title":"Effects of short-term abstinence from escalating doses of d-amphetamine on drug and sucrose-evoked dopamine efflux in the rat nucleus accumbens","volume":"32","author":"Vacca","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib124","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0090-9556(25)08838-5","article-title":"Oral idazoxan bioavailability in rat. Relevance of intestinal and hepatic first-pass effect","volume":"17","author":"Valles","year":"1989","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib125","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.pnpbp.2008.02.004","article-title":"Low dose naltrexone administration in morphine dependent rats attenuates withdrawal-induced norepinephrine efflux in forebrain","volume":"32","author":"Van Bockstaele","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib126","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0893-133X(98)00072-4","article-title":"M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague\u2013Dawley and Wistar rats","volume":"20","author":"Varty","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib127","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S1461145706006638","article-title":"Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive \u03b12 adrenoceptor blockade: experimental evidence","volume":"10","author":"Wadenberg","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1360-0443.2005.00998.x","article-title":"Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis","volume":"100","author":"Wagena","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib129","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0022-3565(24)35389-3","article-title":"Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects","volume":"292","author":"Watkins","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","article-title":"Implications of normal brain development for the pathogenesis of schizophrenia","volume":"44","author":"Weinberger","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib131","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-3565(24)29327-7","article-title":"5-hydroxytryptamine2A receptor inverse agonists as antipsychotics","volume":"299","author":"Weiner","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib132","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1749-6632.1992.tb25967.x","article-title":"Self-stimulation and drug reward mechanisms","volume":"654","author":"Wise","year":"1992","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib133","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00210-002-0592-4","article-title":"Effect of nicotine cessation on the central serotonergic systems in mice: involvement of 5-HT2 receptors","volume":"366","author":"Yasuda","year":"2002","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.003_bib134","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/npp.2008.184","article-title":"Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior","volume":"34","author":"Zhang","year":"2009","journal-title":"Neuropsychopharmacology"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X10000969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X10000969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:49:57Z","timestamp":1760377797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X10000969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":134,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0924977X10000969"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2010.05.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"type":"print","value":"0924-977X"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The \u03b12 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2010.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}